Skip to main content

TYVASO is approved for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3) to improve the ability to exercise.

Skip to main content
Hamburger button
Close button

Reclaim the moments that move you

BREATHE THEM IN
WITH TYVASO FOR PH-ILD

TYVASO is approved for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3) to improve exercise ability.

Catherine’s Story

Hear how TYVASO helped Catherine be more active in her day-to-day life.

Sign up for the Archways Program

If you have been prescribed TYVASO for PH-ILD, you can talk to a Virtual Patient Educator* to learn more and receive support through the Archways program.

*United Therapeutics and the Archways program do not provide medical advice. You are advised to consult with your Healthcare Provider with any specific questions or concerns about your treatment.

Pay as little as $5 per prescription

With the Co-Pay Assistance Card, eligible patients taking TYVASO who enroll may pay as little as a $5 co-pay per month and may receive up to $8000 in savings per year.

How TYVASO can help

TYVASO increases your ability to be active, reduces the amount of strain on your heart, and decreases the chance of PH-ILD getting worse.